Scarica l'app Stockscreener
284.05
0.44%
-1.25
Dopo l'orario di chiusura:
284.15
0.10
+0.04%
Precedente Chiudi:
$285.30
Aprire:
$285.31
Volume 24 ore:
229.09K
Relative Volume:
0.84
Capitalizzazione di mercato:
$31.51B
Reddito:
$5.36B
Utile/perdita netta:
$287.73M
Rapporto P/E:
112.59
EPS:
2.5229
Flusso di cassa netto:
$924.18M
1 W Prestazione:
-5.67%
1M Prestazione:
-17.92%
6M Prestazione:
-12.42%
1 anno Prestazione:
+11.58%
Intervallo 1D:
$283.04
$288.45
Intervallo di 1 settimana:
$283.04
$308.99
Portata 52W:
$196.45
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Nome
Beone Medicines Ltd Adr
Settore
Industria
Telefono
41-616851900
Indirizzo
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Barclays | Overweight |
| 2025-04-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-12-03 | Ripresa | Morgan Stanley | Overweight |
| 2024-09-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-06 | Ripresa | JP Morgan | Overweight |
| 2023-09-12 | Iniziato | Macquarie | Outperform |
| 2023-08-17 | Iniziato | Jefferies | Buy |
| 2023-07-17 | Iniziato | Citigroup | Buy |
| 2023-06-30 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Iniziato | Daiwa Securities | Buy |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-10-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Ripresa | JP Morgan | Overweight |
| 2022-03-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Iniziato | Deutsche Bank | Buy |
| 2021-10-12 | Iniziato | Bernstein | Outperform |
| 2021-10-06 | Aggiornamento | CLSA | Underperform → Buy |
| 2021-03-08 | Iniziato | China Renaissance | Buy |
| 2021-03-01 | Downgrade | CLSA | Outperform → Underperform |
| 2020-11-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-06 | Downgrade | Piper Sandler | Neutral → Underweight |
Mostra tutto
Beone Medicines Ltd Adr Borsa (ONC) Ultime notizie
Capital International Investors Boosts Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital International Sarl Has $50.61 Million Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines Ltd.Sponsored ADR $ONC Stock Position Cut by Capital International Inc. CA - MarketBeat
Capital Group Private Client Services Inc. Reduces Stock Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Pinpoint Asset Management Singapore Pte. Ltd. Has $1.49 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
JPMorgan Chase & Co. Has $16.63 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines Pharma Alliances Contrast With High P/E And Valuation Upside - Sahm
TD Asset Management Inc Takes $9.33 Million Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Price Target Raised to $410.00 - Defense World
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment - Finviz
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
Generali Investments Management Co LLC Takes Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Here's What Important Indicators Reveal About BeOne Medicines Ltd.Sponsored ADR (ONC) Fourth Quarter Results - Bitget
Here's What Key Metrics Tell Us About BeOne Medicines Ltd.Sponsored ADR (ONC) Q4 Earnings - Yahoo Finance
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum - ChartMill
BeOne Medicines (NASDAQ:ONC) Shares Gap Down Following Weak Earnings - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
M&G PLC Has $41.17 Million Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Lowers Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Bernstein Remains a Buy on BeOne Medicines AG (ONC) - Finviz
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire Inc.
Candriam S.C.A. Sells 67,718 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 1,660 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Trial Wins And Sonrotoclax Clearance Meet Valuation Discount - Sahm
3 Stocks to Buy in February - Finviz
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Finviz
Mirae Asset Global Investments Co. Ltd. Acquires 38,992 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 - Finviz
BeOne Medicines Collaboration Extends Safety Modeling As Shares Trade Below Targets - Sahm
Assessing BeOne Medicines (ONC) Valuation After Expanded InSysBio Collaboration On Clinical Trial Modeling - Sahm
Did BeOne’s New Uptrend And Upgraded Earnings Outlook Just Shift Its (ONC) Investment Narrative? - simplywall.st
EMCOR Group, Inc. (NYSE:EME) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT) - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines Earnings Momentum Spurs Valuation Debate And Analyst Optimism - Sahm
Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan - ChartMill
CICC Predicts HSI to Add ZIJIN GOLD INTL/ BEONE MEDICINES/ PICC P&C/ AKESO as New Constituents; STANCHART May Replace HANG SENG BANK - AASTOCKS.com
Assessing BeOne Medicines (ONC) Valuation After A Year Of Strong Shareholder Returns - Sahm
HERIZON-GEA-01 Phase 3 Zanidatamab Combo Data Might Change The Case For Investing In BeOne Medicines (ONC) - Sahm
McDonald’s Upgraded, Netflix Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Chan Henry Lee Sells 664 Shares of BeOne Medicines (NASDAQ:ONC) Stock - Defense World
Beone Medicines Ltd Adr Azioni (ONC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.01%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):